BE HEARD: Bimekizumab 3-Year Data Support Earlier Intervention HS, With Raj Chovatiya, MD, PhD

 (HS) and shorter disease duration demonstrated substantially greater clinical improvement over 3 years of bimekizumab (Bimzelx) treatment than those with severe, longstanding disease — findings that Raj Chovatiya, MD, PhD, MSCI, argues reinforce the urgency of early therapeutic intervention in a condition defined by diagnostic delay.

Chovatiya, clinical associate professor of medicine at Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology + Immunology Research in Chicago, Illinois, presented a post hoc analysis of the BE HEARD extension study (BE HEARD EXT) at the 

2026 American Academy of Dermatology (AAD) Annual Meeting

 held in Denver, Colorado, from March 27-31. The BE HEARD program comprised 2 multicenter, randomized, double-blind, placebo-controlled phase 3 trials (BE HEARD I and II) with a combined enrollment of 1,014 participants evaluating bimekizumab — a dual IL-17A and IL-17F inhibitor — in adults with moderate to severe HS. Patients who completed Week 48 were eligible to enroll in BE HEARD EXT, an open-label extension in which participants received bimekizumab 320 mg subcutaneously every 2 or 4 weeks based on response. The analysis reported at the meeting reflects observed-case data from the 367 patients randomized to bimekizumab from baseline in BE HEARD I and II who completed BE HEARD EXT through Week 148.

The post hoc analysis stratified patients by disease duration quartile and baseline Hurley stage. Among patients in the lowest disease duration quartile (less than 2.38 years since HS diagnosis) with moderate baseline disease (Hurley Stage II), HiSCR90 and HiSCR100 at 3 years were achieved by 74.1% (43/58) and 62.1% (36/58), respectively. By contrast, patients in the highest disease duration quartile (10.74 or more years) with severe baseline disease (Hurley Stage III) achieved HiSCR90 and HiSCR100 at rates of 51.5% (17/33) and 33.3% (11/33), respectively. This separation across response thresholds was sustained across the full 3-year treatment period. In a separate post hoc analysis of the same extension dataset, 86.1% (316/367) of patients who completed Week 148 remained free of acute symptom exacerbation — defined as a 25% or greater increase in abscess and inflammatory nodule count from baseline with an absolute increase of 2 or more — at any scheduled clinic visit through 3 years. Bimekizumab also demonstrated efficacy improvements across all evaluated subgroups in a third post hoc analysis, including by age, sex, BMI, baseline disease duration, and Hurley stage.

Chovatiya noted that the concept of a window of opportunity in HS — in which earlier intervention may limit irreversible structural damage — has been theorized but difficult to test prospectively given the challenges of enrolling patients early in the disease course. He characterized this analysis as among the first to operationalize that question using clinical trial data, and expressed interest in seeing analogous analyses conducted across other approved mechanisms, including oral JAK inhibitors and agents targeting the IL-1 family and chemokine pathways, as the HS pipeline continues to expand. These data were post hoc analyses and should be interpreted with caution as the analyses were not prespecified in the original protocols.

“We talk about this window of opportunity with HS all the time, that if we can intervene early enough, can we change the course of disease and limit any functionally impairing outcomes? And this is really the first step in analyses that really try to take a look at individuals that are in the early parts of their disease and see what their overall trajectory looks like,” Chovatiya said.

Chovatiya previously reported serving as an advisor, consultant, speaker, and/or investigator for AbbVie, Amgen, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Formation Bio, Galderma, Genentech, GSK, Incyte, LEO Pharma, L’Oréal, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., Regeneron, RAPT, Sanofi, Sitryx, and UCB.

Chovatiya R. Bimekizumab efficacy by disease duration and severity in moderate to severe hidradenitis suppurativa: 3-year phase 3 results from BE HEARD EXT. 2026. AAD. #73498.

UCB. UCB announces new BIMZELX® (bimekizumab-bkzx) data at AAD showing durable symptom control throughout three years in hidradenitis suppurativa. Press release. March 27, 2026. Accessed [date]. 

https://www.ucb.com/newsroom/press-releases/article/ucb-announces-new-bimzelxr-bimekizumab-bkzx-data-at-aad-showing-durable-symptom-control-throughout-three-years-in-hidradenitis-suppurativa

Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48 week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. 

Videos

Extension data from BE HEARD showed that patients with shorter disease duration and lower baseline severity achieved higher response rates than those with longstanding, more severe disease.


News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

, and lupus nephritis, including late-breaking trial results for iptacopan, semaglutide, and atrasentan, as well as emerging approaches such as CAR-T cell therapy. 

Together with insights from large observational cohorts like NEPTUNE and CureGN, these findings reflect a shift toward precision medicine, with growing emphasis on linking molecular mechanisms to clinical outcomes to improve patient selection and slow disease progression.

editorial team has compiled 5 of the most informative discussions, along with key data from WCN. Catch up on key findings from the conference below:

​​NEPTUNE and CureGN Driving Precision Nephrology Forward, With Alessia Fornoni, MD, PhD

WCN 2026 Recap: 5 Key Updates in Kidney Disease to Know

In an interview, Alessia Fornoni, MD, PhD, Professor of Medicine, Molecular and Cellular Pharmacology, and Biochemistry at the University of Miami Miller School of Medicine and Director and Chair of the Peggy and Harold Katz Drug Discovery Center, said NEPTUNE and CureGN are reshaping how clinicians and researchers conceptualize kidney disease, shifting the focus from histologic patterns to underlying molecular mechanisms and patient-specific biology. 

These natural history studies provide a critical foundation for linking clinical presentation, demographics, and long-term outcomes, enabling a more precise understanding of disease heterogeneity through integrated genomic and molecular analyses.

From FLOW to REMODEL: Understanding Semaglutide in CKD, With Katherine Tuttle, MD

In an interview, Katherine Tuttle, MD, explained that REMODEL builds on the success of the FLOW trial, which demonstrated significant reductions in kidney events, cardiovascular outcomes, and all-cause mortality with semaglutide, ultimately leading to its US Food and Drug Administration (FDA) approval in chronic kidney disease. 

While those findings established clinical efficacy, they did not fully elucidate the underlying biology. REMODEL was designed as a mechanistic “deep dive,” integrating advanced imaging, kidney biopsy, and transcriptomic analyses to better understand treatment effects. By linking mechanistic signatures to outcomes, the study provides a framework for identifying responders and tailoring therapy.

REMODEL: Mechanistic Insights Into Semaglutide in CKD, With Petter Bjornstad, MD

Can CAR-T Cell Therapy Transform Lupus Nephritis Care? With Brad Rovin, MD

The emergence of CAR-T cell therapy represents a potentially transformative step in lupus nephritis, reflecting the field’s broader shift toward precision medicine and targeted immune modulation. In an interview, Brad Rovin, MD, explained that treatment has historically relied on broadly acting immunosuppressive therapies such as cyclophosphamide or mycophenolate, which “treat everything” but fail to account for biological variability across patients.

This one-size-fits-all approach is increasingly being replaced by more tailored strategies, particularly as more than half of patients do not achieve complete clinical remission with existing options.

Kidney Compass: New 2-Year APPLAUSE-IgAN Data for Iptacopan at WCN 2026

, hosts Shikha Wadhwani, MD, MS, and Brendon Neuen, MBBS, PhD, spoke with Vlado Perkovic, MBBS, PhD, about newly presented 2-year eGFR slope data from the phase 3 APPLAUSE-IgAN trial evaluating iptacopan. 

Perkovic emphasized the key remaining question: whether the 38% reduction in proteinuria observed at 9 months translates into long-term kidney protection in this high-risk population, characterized by median proteinuria of approximately 1.7 g/g and rapid progression in the placebo arm, where eGFR declined by >6 mL/min/1.73 m² per year.

 APPLAUSE-IgAN: Iptacopan (Fabhalta) Exhibits 49.3% Slower eGFR Decline in IgAN Patients Than Placebo

Kidney Compass: ASSIST Trial Shows Atrasentan Benefit on Top of SGLT2 Inhibitors

, hosts Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, sat down with Hiddo Heerspink, PhD, PharmD, to discuss the phase 2 ASSIST trial evaluating the efficacy and safety of atrasentan in combination with SGLT2 inhibitors. 

The study was intentionally designed to reflect a rapidly evolving standard of care, as increasing evidence supports SGLT2 inhibitors in chronic kidney disease. As a result, ASSIST addresses a key clinical question: whether additional therapies such as atrasentan can provide incremental benefit when layered onto existing treatment.

Articles

WCN 2026 underscored a rapid pivot toward precision nephrology, integrating large natural history cohorts with mechanism-driven interventional trials. NEPTUNE and CureGN are reframing kidney disease classification around molecular endotypes rather than histology, enabling tighter links between biology and long-term outcomes. Semaglutide’s clinical benefit in CKD is being complemented by REMODEL’s biopsy-, imaging-, and transcriptomic-based mechanistic mapping to identify responders. In immune-mediated disease, CAR-T signals a move beyond nonspecific immunosuppression in lupus nephritis. Late-breaking IgAN and CKD trials evaluated complement and endothelin pathway targeting atop modern standards.

HCPLive’s editorial team has compiled 5 of the most informative discussions, along with key data from the WCN. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Chronic Kidney Disease

WCN 2026 Recap: 5 Key Updates in Kidney Disease to Know 

Andrew Yockey, PhD, assistant professor at the University of Mississippi.

Sex, Age, Racial Disparities Persist in Adolescent Depression, With Andrew Yockey, PhD

Although national data show a nearly 40% decline in adolescent 

 between 2021 and 2024, persistent disparities across sex, age, and race and ethnicity continue to shape clinical risk assessment and care delivery, according to Andrew Yockey, PhD, assistant professor at the University of Mississippi.

, Yockey discussed findings from a recent analysis of the National Survey on Drug Use and Health data, which reported a 

decrease in past-year major depressive episodes

 among adolescents aged 12–17 years from 20.5% in 2021 to 14.8% in 2024. Despite the overall improvement, girls, older teens, and multiracial youth were more likely to experience depression. Girls had 3-fold greater odds of having depression than boys.

Yockey emphasized that clinicians should respond to this disparity with more targeted and developmentally informed screening and treatment approaches. He noted that girls may be more vulnerable to risk factors such as rumination, body image concerns, and social comparison, all of which can contribute to depressive symptoms during adolescence. He also stressed the importance of screening earlier and more frequently, rather than relying on single assessments.

“Someone gets screened, and then they don’t get screened for another 10 years,” Yockey said. “This just does not go away.”

He encouraged clinicians to move beyond the misconception that depression primarily presents as sadness. Instead, screening should include irritability, somatic complaints, lack of motivation, and other nontraditional symptoms. Yockey also pointed to social media exposure, peer dynamics, academic pressure, and gender expectations as additional contributors that clinicians may consider during assessment.

The study also found that older adolescents had greater odds of major depressive episodes, consistent with the broader understanding that late adolescence is a critical developmental period for mental health challenges.

“This a very stressful time in your life,” Yockey said. “If you think about adolescence, it's navigating the unknowns in life…it's also discovering yourself.”

Older adolescents are more likely to experiment with substances, encounter academic and social pressures, and navigate transitions toward independence, he noted. These stressors can coincide with the onset of mental health disorders, making early and repeated screening particularly important. Yockey also highlighted the role of parent education, encouraging clinicians to help families recognize warning signs and support adolescents as they approach adulthood.

Yockey noted that clinicians need to increase screening and raise awareness of mental health difficulties.

“We're still in this phase that, when people hear about depression, it's, ‘oh, just don't be sad.’ Well, that's easier said than done,” he said.

The analysis also identified racial and ethnic differences, with multiracial teens being more likely to experience depression. While some minoritized groups reported lower odds of depression, Yockey cautioned that these findings may reflect underdiagnosis rather than lower true prevalence. For example, Black adolescents may report lower diagnosed depression but experience greater unmet mental health needs and more severe outcomes.

Yockey attributed these patterns to multiple factors, including reduced access to care, stigma surrounding mental health, and cultural differences in symptom expression. He encouraged clinicians not to rely solely on screening scores and instead engage adolescents in conversations about how they experience stress, sadness, or irritability. Asking culturally sensitive questions may help identify symptoms that standardized tools miss.

Building trust with families and communities was another key recommendation. Yockey noted that historical mistrust and stigma continue to affect engagement in mental health care. Involving caregivers, respecting family beliefs, and addressing misconceptions may improve uptake and retention in treatment.

He also highlighted the importance of follow-up, noting that minoritized adolescents are more likely to disengage from care. Strategies such as early follow-up visits, reminder check-ins, and monitoring engagement, not just symptoms, may help improve continuity of care.

Yockey stressed that clinicians should not assume improvements at the population level translate to reduced risk for individual patients, particularly those within greater-risk groups.

Andrew Yockey R, Apu A, Grigsby T, Bleasdale J, Mattingly D, Hoopsick R. Decreasing prevalence in youth depressive episodes: Evidence from the 2021-2024 national survey on drug use and health. J Psychiatr Res. 2026 Mar 25;198:188-191. 

Yockey discusses why girls, older teens, and multiracial youth remain at greater risk for depression despite overall post-pandemic improvements.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

March delivered a wave of impactful updates in cardiology, with major trial readouts, regulatory progress, and new guideline recommendations shaping the evolving landscape of cardiovascular care, many of which were highlighted at the American College of Cardiology’s Annual Scientific Session (ACC.26). From pulmonary arterial hypertension (PAH) to atrial fibrillation and hypertrophic cardiomyopathy, the month showcased continued momentum in both therapeutic innovation and clinical strategy.

New data from several major studies took center stage, including ADVANCE OUTCOMES, which demonstrated ralinepag’s potential to slow disease progression in PAH, and CHAMPION-AF, which reinforced the role of device-based left atrial appendage closure as an alternative to anticoagulation. At the same time, emerging data from trials like SCOUT-HCM and MOMENTUM offered new insights into underrecognized disease drivers and expanding treatment opportunities across patient populations.

Beyond trial data, the release of updated ACC/AHA dyslipidemia guidelines provided a comprehensive framework for lipid management, while regulatory movement for agents like lorundrostat signaled continued progress in hypertension care.

Here’s a look at the key cardiology headlines from March 2026 you may have missed:

ADVANCE OUTCOMES: Ralinepag Outperforms Placebo in Slowing Disease Progression in PAH

On March 2, 2026, United Therapeutics Corporation announced that its investigative prostacyclin (IP) receptor agonist ralinepag met its primary endpoint of reducing worsening clinical events in patients with pulmonary arterial hypertension (PAH) in the phase 3 ADVANCE OUTCOMES study.

Ralinepag demonstrated a 55% reduction in clinical worsening event risk (HR 0.45; 95% CI, 0.33-0.62; 

 <.0001) and saw durable efficacy in delaying disease progression – 80% of patients were on dual background therapy, and 70% were considered WHO/NYHA functional class II at baseline. Ralinepag also improved 6MWD and NT-proBNP compared to placebo, with increased odds of achieving improvement by 47% from baseline to week 28.

Lorundrostat Secures FDA NDA Acceptance for Hypertension, Falls Short in Phase 2 OSA Trial

On March 9, 2026, the FDA accepted Mineralys Therapeutics’ New Drug Application (NDA) for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs. The application was backed by positive data from the phase 3 Launch-HTN and phase 2 Advance-HTN trials demonstrating favorable safety and blood pressure reduction in adults with hypertension. With the acceptance, the FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026.

Behind the Guidelines: Understanding 2026 ACC/AHA Dyslipidemia Guidelines

The American College of Cardiology, the American Heart Association, and 9 other leading medical associations issued an updated guideline for the management of dyslipidemia. The document consolidates evidence-based recommendations for managing dyslipidemias into a single resource, offering a comprehensive tool for how to best assess and treat various blood lipids to effectively lower an individual’s risk of developing ASCVD.

In this 9-part series, Ann Marie Navar, MD, PhD, a writing committee member, and Pamela Morris, MD, vice chair of the writing committee, break down key questions and changes to the 2026 ACC/AHA Dyslipidemia guidelines.

Updated ACC/AHA Dyslipidemia Guidelines Incorporate LDL-C Goals, Lp(a) Focus, With Deepak Bhatt, MD, MPH

CHAMPION-AF: Left Atrial Appendage Closure Noninferior to NOACs

The CHAMPION-AF trial demonstrated the noninferiority of device-based left atrial appendage closure (LAAC) compared to non-vitamin K antagonist oral anticoagulant (NOAC) therapy in preventing adverse events in patients with atrial fibrillation (AF). The trial enrolled 3000 patients with non-valvular AF at elevated stroke risk, who were then randomized to either the Watchman FIx device or an approved NOAC. Ultimately, a composite primary efficacy endpoint cardiovascular death, stroke, or systemic embolism occurred in 81 patients among the device group and 65 in the NOAC group, resulting in a difference of 0.9 percentage points.

SCOUT-HCM: Mavacamten Outperforms Placebo in Adolescents With HCM, With Joseph Rossano, MD, MS

Mavacamten successfully demonstrated greater reductions in left ventricular outflow compared to placebo in adolescent patients with oHCM in the SCOUT-HCM trial. Joseph Rossano, MD, MS, co-director of the Cardiac Center at the Children’s Hospital of Philadelphia, presented the data at ACC.26, demonstrating the drug’s efficacy among 44 patients. Mean Valsalva left ventricular outflow tract gradient ultimately decreased by 48.5 mmHg in the mavacamten arm compared to -0.5 mmHg in the placebo arm, and Rossano and colleagues ultimately reported few significant adverse events.

MOMENTUM: Hypercortisolism Present in 1-in-4 with Resistant Hypertension

Endogenous hypercortisolism was identified in more than a quarter of patients with resistant hypertension, according to findings presented at ACC. Results from the screening portion of the MOMENTUM trial results suggest the condition may be a substantially more common and underrecognized driver of treatment-resistant hypertension than current clinical practice assumes.

Evolocumab Reduces CV Risk in Non-Atherosclerotic Patients With Diabetes, With Nicholas Marston, MD, MPH

A secondary analysis of the VESALIUS-CV trial, presented at ACC by Nicholas Marston, MD, MPH, a preventive cardiologist at Brigham and Women’s Hospital, highlighted oral PCSK9 inhibitor evolocumab’s capacity to lower LDL-C in high-risk patients without a history of major cardiovascular events and with diabetes. A composite endpoint including coronary heart disease death, myocardial infarction, or ischemic stroke – as well as a 4-part endpoint including ischemia-driven arterial revascularization – occurred far less among patients treated with evolocumab compared to those receiving placebo.

March 2026 cardiology updates feature key ACC.26 data, new guidelines, and advances in PAH, AF, hypertension, and lipid management.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

Atherosclerotic Cardiovascular Disease

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

7 Cardiology Headlines You Missed in March 2026

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

The first quarter of 2026 brought regulatory approvals, late-stage psychedelic data, and increased use of at-home neuromodulation and artificial intelligence–supported mental health tools that reflected rapid change across psychiatry. 

 decisions expanded treatment options for acute bipolar I disorder, schizophrenia, and 

, alongside progress toward a potential new nonstimulant therapy for ADHD.

Q1 developments emphasized faster-acting therapies, at-home treatment delivery, and technology-driven care innovation. This recap spotlights 7 psychiatry headlines in Q1.

FDA Updates in Psychiatry: New Approvals 

FDA Approves Milsaperidone for Acute Bipolar I Disorder, Schizophrenia

The FDA approved Vanda Pharmaceuticals’ milsaperidone (BYSANTI) for the treatment of acute bipolar I disorder and schizophrenia, expanding pharmacologic options for patients experiencing acute psychiatric episodes. Clinical data supporting approval demonstrated significant symptom improvement across key measures, with tolerability findings consistent with expectations for second-generation antipsychotics. The approval adds another mechanism for clinicians managing acute mood and psychotic symptoms.

FDA Approves ProlivRx, First At-Home Neuromodulation Device for MDD

The FDA approved Neurolief’s ProlivRx, the first at-home neuromodulation device for MDD. The decision represents a shift toward decentralized treatment models, allowing patients to receive neuromodulation therapy outside clinic settings. Investigators highlighted potential benefits for access, adherence, and reduced logistical burden, particularly for individuals unable to attend frequent in-office sessions.

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

The FDA accepted the new drug application for centanafadine for adult and pediatric ADHD and granted priority review. Centanafadine, developed by Otsuka, is a triple reuptake inhibitor targeting norepinephrine, dopamine, and serotonin, representing a potential nonstimulant option. The FDA assigned centanafadine a Prescription Drug User Fee Act (PDUFA) target action date of July 24, 2026.

Promising Phase 2 & Phase 3 Data: Rapid-Acting Psychedelic Therapies 

COMP360 Psilocybin Meets Primary Endpoint in Second Phase 3 Trial for TRD

The second phase 3 trial of Compass Pathways’ COMP360 psilocybin met its primary endpoint in treatment-resistant depression (TRD), reinforcing prior late-stage findings. Investigators reported that two 25 mg COMP360 doses administered 3 weeks apart produced a statistically significant reduction in depressive symptom severity at week 6 compared with a 1 mg dose control. The findings support the potential role of psychedelic-assisted therapy in patients with limited treatment response.

COMP360 Psilocybin Shows Rapid, Durable Effect in TRD, With Steve Levine, MD

Single-Day GH001 for TRD Shows Rapid Response, With Michael E. Thase, PhD

A Phase 2b trial evaluating inhaled GH001 demonstrated rapid and clinically meaningful antidepressant effects following a single-day individualized dosing session. Michael E. Thase, MD, of the University of Pennsylvania, highlighted the rapid onset and potential scalability of a single-session psychedelic-based intervention compared with multi-session treatment models. The study showed that GH001 could improve depression severity within 1 week.

Intravenous DMT (SPL026) Demonstrates Significant MDD Reduction in Phase 2a Trial

Phase 2a data for SPL026, an intravenous formulation of dimethyltryptamine (DMT), showed significant reductions in depressive symptoms among patients with MDD. The therapy was associated with a rapid onset of action, adding to the growing body of evidence supporting short-duration psychedelic interventions.

SPL026 is a short-acting serotonergic psychedelic that acts primarily as a 5-HT2A receptor agonist. Unlike psilocybin, which can produce psychoactive effects lasting 4 to 6 hours, intravenous DMT has a shorter duration of acute subjective effects, often under 30 minutes.

Helus Pharma stated they will not be advancing the intravenous formulation in its current form but are using the trial insights to develop HLP004, a proprietary novel serotonergic agonist under investigation for generalized anxiety disorder (GAD).

Your Patient's New Therapist Is an AI. Now What?

Increasing patient use of generative artificial intelligence tools for mental health support sparked discussion around clinical oversight and safety. Experts noted that patients are turning to AI for therapy-like conversations, raising questions about accuracy, crisis management, and appropriate clinician guidance. Although AI may improve access and reduce stigma, clinicians emphasized that these tools should complement, not replace, professional mental health care, particularly for complex or high-risk cases.

The first quarter of 2026 underscored accelerating diversification in psychiatric therapeutics and care delivery, spanning novel antipsychotic options, decentralized neuromodulation, and rapid-acting psychedelic platforms. Regulatory actions included approval of milsaperidone for acute bipolar I disorder and schizophrenia, authorization of an at-home neuromodulation device for MDD, and priority review of a triple reuptake inhibitor as a potential nonstimulant ADHD treatment. Late-stage and mid-stage trials supported short-duration psychedelic interventions with rapid antidepressant effects, while generative AI’s growing patient adoption intensified scrutiny around safety, oversight, and appropriate clinical integration.

FDA approvals, at-home neuromodulation, phase 3 psychedelic data, and rising AI therapy use impacted the psychiatry field in the first quarter of 2026.

Q1 2026 Recap: Psychiatry News and Updates

Narendra Singh, MD, is an assistant professor at Mercer University Atlanta Campus and the director of clinical research at NSC Cardiology.

Singh discusses his analysis of all 3 parts of the NODE-301 phase 3 trial, investigating the recently approved CBB’s potential risk of hypotension.

Strategic Alliance Partnership

Self-Administered Etripamil for PSVT Has Minimal Blood Pressure, Heart Rate Effects, With Nerendra Singh, MD

Q1 2026 GI updates include advances in IBD and IBS therapies, long-term data, and new insights into access challenges for younger patients.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Irritable Bowel Syndrome

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Q1 2026 Recap: Gastroenterology News and Updates

Hematology

Breaking News

12 New Recommendations For Anticoagulant Prophylaxis in Pediatric Patients at Risk for Venous Thromboembolism

Michelle O'Donoghue, MD, is the McGillycuddy-Logue Endowed Chair in Cardiology at Brigham and Women's Hospital and associate professor at Harvard Medical School

O’Donoghue addresses the inherent limitations in the ACS guidelines, from the constant influx of further research to the ambiguity of certain treatment recommendations.

Structural Heart Disease

Gray Areas and Controversies in the 2025 ACS Guidelines, With Michelle O’Donoghue, MD, MPH

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Sanofi’s dual TSLP/IL‑13 bispecific cuts asthma exacerbations and shrinks nasal polyps, while atopic dermatitis results disappoint.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Lunsekimig Meets End Points in Asthma and CRSwNP, Misses in Atopic Dermatitis

Q1 2026 hepatology highlights include advances in MASH, hepatitis B, gene editing for AATD, and the first approved therapy for pruritus in PBC.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Alpha-1 antitrypsin deficiency

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Q1 2026 Recap: Hepatology News and Updates

2-year results from phase 3 APPLAUSE-IgAN demonstrate slower eGFR decline, reduced composite kidney failure, and proteinuria in IgAN patients treated with iptacopan. 


APPLAUSE-IgAN: Iptacopan (Fabhalta) Exhibits 49.3% Slower eGFR Decline in IgAN Patients Than Placebo

Panelists discuss the signs, symptoms, diagnostic delays, and classification of obstructive hypertrophic cardiomyopathy, including how it differs from other forms and its implications for clinical management.

Video Series

Recognizing and Classifying Obstructive Hypertrophic Cardiomyopathy

Panelists discuss the challenges and gaps in diagnosing hypertrophic cardiomyopathy, including variability in clinical practice, underdiagnosis, and opportunities to improve detection.

Diagnosing Hypertrophic Cardiomyopathy: Challenges and Gaps in Clinical Practice

Learn when to switch to IV iron, which formulations need fewer infusions, and how to manage rare reactions, MRI issues, and hypophosphatemia.

Latest News

BE HEARD: Bimekizumab 3-Year Data Support Earlier Intervention HS, With Raj Chovatiya, MD, PhD

WCN 2026 Recap: 5 Key Updates in Kidney Disease to Know

Sex, Age, Racial Disparities Persist in Adolescent Depression, With Andrew Yockey, PhD

7 Cardiology Headlines You Missed in March 2026

Q1 2026 Recap: Psychiatry News and Updates